Please use this identifier to cite or link to this item:
|Title:||Inhibition of Leishmania (Leishmania) amazonensis growth and infectivity by aureobasidin A|
|Authors:||Tanaka, Ameria K. [UNIFESP]|
Valero, Valderez B [UNIFESP]
Takahashi, Helio K. [UNIFESP]
Straus, Anita H. [UNIFESP]
Universidade Federal de São Paulo (UNIFESP)
|Publisher:||Oxford Univ Press|
|Citation:||Journal of Antimicrobial Chemotherapy. Oxford: Oxford Univ Press, v. 59, n. 3, p. 487-492, 2007.|
|Abstract:||Objectives: To study the effect of aureobasidin A, an inhibitor of inositol phosphorylceramide (IPC) synthase, on Leishmania growth and infectivity.Methods: Effects of aureobasidin A were determined for: (i) promastigote growth in axenic culture; (ii) promastigote infectivity in macrophage monolayers; (iii) development of footpad lesions in BALB/c mice; (iv) differentiation of amastigotes into promastigotes.Results: Aureobasidin A (20 mu M) inhibited 90% of Leishmania (Leishmania) amazonensis promastigote growth in axenic culture, but the parasites remained viable, i.e. growth curves returned to normal after aureobasidin A was removed from culture medium. the aureobasidin A IC50 was determined by MTT assay as 4.1 mu M for L. (L.) amazonensis promastigotes, 12.6 mu M for Leishmania (Leishmania) major and 13.7 mu M for Leishmania (Viannia) braziliensis. There was a significant delay in infection when L. (L.) amazonensis promastigotes pre-treated with aureobasidin A were inoculated into BALB/c mouse footpads. When aureobasidin A was added to cultured macrophages infected with amastigotes, the number of infected macrophages was reduced by >90%.Conclusions: Aureobasidin A is an interesting pharmacological tool to investigate the effect of lipid metabolism inhibition in Leishmania spp.|
|Appears in Collections:||Em verificação - Geral|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.